When to conduct hepatic impairment studies and when modeling may be enough
How to decide if a hepatic impairment study is required, choose the right study design,…
Zoe BarterJuly 13, 2026
Dosimetry for radiopharmaceutical therapy: From measurement to dose justification
Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…
Hunter Stephens, PhDJuly 7, 2026
The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors
The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors
Learn how PBPK and QSP modeling support faster drug development by enabling smarter dose selection,…
CertaraJuly 1, 2026
Enhancing clinical trials with real-world evidence in pregnancy research
Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…
Alekhya Lavu, PhD, PharmDJune 26, 2026
Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development
Integrated offering combines drug development, regulatory, commercial, and investor strategy expertise to help early-stage biotech…
Danielle PillsburyJune 23, 2026
Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies
Discover how endogenous ligand competition was incorporated into a whole-body PBPK model to improve prediction…
CertaraJune 23, 2026
Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study
Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…
CertaraJune 23, 2026
Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling
Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…
CertaraJune 22, 2026
